THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 121 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2023. The put-call ratio across all filers is 0.98 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $433,821 | +250.4% | 41,915 | +267.3% | 0.00% | – |
| Q1 2023 | $123,820 | -27.4% | 11,412 | -24.9% | 0.00% | – |
| Q4 2022 | $170,544 | +48.3% | 15,200 | +33.7% | 0.00% | – |
| Q3 2022 | $115,000 | +12.7% | 11,368 | +1.1% | 0.00% | – |
| Q2 2022 | $102,000 | -34.2% | 11,249 | -30.8% | 0.00% | – |
| Q1 2022 | $155,000 | -98.7% | 16,260 | -95.7% | 0.00% | -100.0% |
| Q4 2016 | $12,095,000 | – | 379,400 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chescapmanager LLC | 1,134,718 | $23,160,000 | 2.47% |
| Baupost Group | 8,735,168 | $178,285,000 | 1.42% |
| Orbimed Advisors | 6,219,110 | $126,932,000 | 1.19% |
| CM Management, LLC | 50,000 | $1,021,000 | 0.76% |
| Tekla Capital Management LLC | 456,296 | $9,313,000 | 0.32% |
| Rock Springs Capital Management LP | 682,600 | $13,932,000 | 0.30% |
| Virtus ETF Advisers LLC | 32,871 | $671,000 | 0.28% |
| Cormorant Asset Management, LP | 550,000 | $11,226,000 | 0.25% |
| DAFNA Capital Management LLC | 41,165 | $840,000 | 0.20% |
| PEREGRINE CAPITAL MANAGEMENT LLC | 484,206 | $9,883,000 | 0.18% |